Markets are waiting today to see how the U.S. economy performed in Q3. Plus, Novo Nordisk has capped off a difficult year with a decisive victory, with the FDA approving sale of its weight-loss pill for U.S. consumers. And Japan may have calmed its currency markets - for now.
Today’s recommended read: Guns and gold win in 2025, but other 'safety' trades bomb by Mike Dolan
Subscribe to Mike Dolan's Morning Bid newsletter, and check out his columns on Reuters Open Interest
Produced by Eliza Davis Beard and Ethan Plotkin
Sound engineering and music by Sebastian and Josh Sommer
Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices.
You may also visit megaphone.fm/adchoices to opt out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices